ストロークに対するズームシステムを併用した連続二重吸引法 (ADAPT 2 0)
脳卒中に対するZoomシステムを用いた連続二重吸引技術の臨床評価(ADAPT 2.0)
This study is designed to evaluate the effectiveness, safety and clinical performance of ADAPT 2.0, first-line aspiration neurothrombectomy with Zoom System with Continuous Dual Aspiration Technique (CDAT).
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (推定)
入学
連絡先と場所
研究連絡先
研究連絡先
- 名前:Pojai Phattanagosai
- 電話番号:650-740-7703
- メール:pphattanagosai@Imperativecare.com
研究連絡先のバックアップ
- 名前:Emma Pham
- 電話番号:408-421-7684
- メール:epham@imperativecare.com
研究場所
-
-
Alabama
-
Huntsville、Alabama、アメリカ、35801
- 募集
- Huntsville Hospital
-
コンタクト:
- Farrar Hickey
-
主任研究者:
- R. Dana Tomalty, MD
-
-
California
-
Walnut Creek、California、アメリカ、94598
- 募集
- John Muir Health
-
主任研究者:
- Benjamin Yim, MD
-
コンタクト:
- Melenie Aaron
-
-
Florida
-
Tampa、Florida、アメリカ、33606
- 募集
- University of South Florida
-
主任研究者:
- Maxim Mokin, MD
-
コンタクト:
- Kilaun Robinson
-
-
Georgia
-
Marietta、Georgia、アメリカ、30060
- 募集
- Wellstar Kennestone Hospital
-
コンタクト:
- Autumn Lee
-
主任研究者:
- Ahmad Khaldi, MD
-
-
Louisiana
-
Lafayette、Louisiana、アメリカ、70503
- 募集
- Ochsner Clinic Foundation (Lafayette)
-
主任研究者:
- Shail Thanki, MD
-
New Orleans、Louisiana、アメリカ、70121
- 募集
- Ochsner Clinic Foundation
-
主任研究者:
- James Milburn, MD
-
コンタクト:
- Jessica Henry
-
-
Maryland
-
Baltimore、Maryland、アメリカ、21201
- 募集
- University of Maryland
-
主任研究者:
- Jacob Cherian, MD
-
コンタクト:
- Katie Henry
-
-
Minnesota
-
Minneapolis、Minnesota、アメリカ、55407
- 募集
- Allina Health
-
コンタクト:
- Emeryth Beloy
-
主任研究者:
- Collin Torok, MD
-
-
New York
-
Albany、New York、アメリカ、12208
- 募集
- Albany Medical College
-
主任研究者:
- Alexandra Paul, MD
-
コンタクト:
- Chelsey Large
-
Buffalo、New York、アメリカ、14203
- 募集
- University at Buffalo Neurosurgery
-
主任研究者:
- Jason Davies, MD
-
コンタクト:
- Ellen Carl
-
New York、New York、アメリカ、10065
- 募集
- Weill Cornell Medicine
-
コンタクト:
- Hanah Hwang
-
主任研究者:
- Amol Mehta, MD
-
New York、New York、アメリカ、10029
- 募集
- Icahn School of Medicine at Mount Sinai
-
コンタクト:
- Kevin Buttet
-
主任研究者:
- Michael T Caton, MD
-
Syracuse、New York、アメリカ、13210
- 募集
- SUNY Upstate Medical Center
-
コンタクト:
- Saptarshi Prachi
-
主任研究者:
- Haydn Hoffman, MD
-
The Bronx、New York、アメリカ、10467
- 募集
- Montefiore Medical Center
-
コンタクト:
- Genesis Liriano
-
主任研究者:
- Amanda Baker, MD
-
-
Ohio
-
Cincinnati、Ohio、アメリカ、45220
- 募集
- TriHealth Good Samaritan Hospital
-
主任研究者:
- Andrew Ringer, MD
-
コンタクト:
- Mehnaaz Ali
-
Columbus、Ohio、アメリカ、43221
- 募集
- The Ohio State University Wexner Medical Center
-
主任研究者:
- Patrick Youssef, MD
-
主任研究者:
- Shahid Nimjee, MD
-
コンタクト:
- Edward Belizaire
-
-
Oklahoma
-
Oklahoma City、Oklahoma、アメリカ、73104
- 募集
- University of Oklahoma, Health Science Center
-
主任研究者:
- Hakeem Shakir, MD
-
コンタクト:
- Sanaa Hameed
-
-
South Carolina
-
Greenville、South Carolina、アメリカ、29605
- 募集
- Prisma Health - Upstate
-
コンタクト:
- Shawn Manos
-
主任研究者:
- Jan Vargas Machaj, MD
-
-
Tennessee
-
Knoxville、Tennessee、アメリカ、37902
- 募集
- Fort Sanders Regional Medical Center
-
コンタクト:
- Cameron Carter
-
主任研究者:
- Robert Hixson, MD
-
Memphis、Tennessee、アメリカ、38120
- 募集
- Semmes Murphey Foundation
-
主任研究者:
- Lucas Elijovich, MD
-
コンタクト:
- Wendell Barnett
-
-
Texas
-
Kingwood、Texas、アメリカ、77339
- 募集
- HCA Houston Healthcare Kingwood
-
主任研究者:
- Mohamad Ezzeldin, MD
-
コンタクト:
- Swathi Potla
-
San Antonio、Texas、アメリカ、78229
- 募集
- Methodist Healthcare System of San Antonio
-
コンタクト:
- Samantha Franklin
-
主任研究者:
- Lee Birnbaum, MD
-
San Antonio、Texas、アメリカ、78229
- 募集
- University of Texas Science Health Center at San Antonio
-
主任研究者:
- Justin Mascitelli, MD
-
コンタクト:
- Athena Lazaris-Conner
-
-
Utah
-
Salt Lake City、Utah、アメリカ、84112
- 募集
- University of Utah
-
コンタクト:
- Andrew Grandemange
-
主任研究者:
- Robert Rennert, MD
-
-
Virginia
-
Falls Church、Virginia、アメリカ、22042
- 募集
- Inova Fairfax Medical Campus
-
コンタクト:
- Lauren Monroe
-
主任研究者:
- James McEachern, MD
-
-
Washington
-
Spokane、Washington、アメリカ、99204
- 募集
- Providence Sacred Heart Medical Center and Children's Hospital
-
コンタクト:
- Kyle Kramer
-
主任研究者:
- Christopher Zylak, MD
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Adult subjects with acute ischemic stroke secondary to large vessel occlusion (LVO) meeting the study eligibility criteria and providing written informed consent.
説明
Inclusion Criteria:
- Subject is ≥ 18 years of age
- Subject or legally authorized representative has provided written informed consent prior to any study-specific procedures and no later than 72 hours after the index procedure
- Pre-stroke mRS 0-2
- Subject is undergoing or has undergone an aspiration thrombectomy using the Zoom System with Continuous Dual Aspiration Technique (CDAT) as the first line device within its intended use
Exclusion Criteria:
- Subjects with a life expectancy of less than 6 months
- Female subject who is known to be pregnant at time of admission
- Any intracranial hemorrhage in the qualifying head CT or MRI
- Presence of tandem internal carotid artery occlusion, multiple occlusion locations (e.g., cavernous ICA and M1, separate M2 occlusions, etc.), or occlusions in multiple territories (e.g., MCA and ACA, bilateral, etc.).
- In the opinion of the Investigator, the patient is not a suitable candidate for intervention with the Zoom System
- Subject is currently enrolled in or planned to be enrolled in any concurrent interventional study that may impact the safety or performance data collected in this study
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:PROSPECTIVE
グループ/コホートの数
コホートと介入
グループ/コホートグループ/コホート |
介入・治療介入・治療 |
|---|---|
|
ADAPT 2.0: Zoom System with Continuous Dual Aspiration Technique (CDAT)
The Zoom System is intended to be used as the first-line device and utilized within the FDA-cleared indications for use, consistent with the approved labeling and intended anatomical targets. |
Aspiration neurothrombectomy using Zoom System with Continuous Dual Aspiration Technique (CDAT)
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Proportion of patients achieving modified Thrombolysis in Cerebral Infarction (mTICI) score of ≥2c at the end of procedure, as adjudicated by independent core-lab
時間枠:End of procedure
|
mTICI scale ranges from 0 to 3, with higher scores indicating better reperfusion. mTICI 0: No antegrade reperfusion; mTICI 1: Antegrade reperfusion past initial occlusion, limited distal filling; mTICI 2a: Antegrade reperfusion of less than half (<50%) of the previously occluded target artery's ischemic territory; mTICI 2b: Antegrade reperfusion of more than half (≥50%) of the previously occluded target artery's ischemic territory; mTICI 2c: Near-complete (90-99%) reperfusion, or filling of all distal branches with slower flow; mTICI 3: Complete antegrade reperfusion of all branches |
End of procedure
|
|
Rate of Embolization to New Territory (ENT) on final angiography at the end of the procedure by investigator assessment
時間枠:End of procedure
|
Embolization to New Territory (ENT), defined as the presence of new occlusions on final angiography that occur in vascular territories remote from those effected by index stroke, as assessed by the investigator |
End of procedure
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Time to achieve mTICI≥2c, defined as groin puncture to investigator assessment for mTICI≥2c
時間枠:Intraprocedural
|
The time from groin puncture to mTICI (modified treatment in cerebral infarction) score ≥ 2c using study device and technique. mTICI scale ranges from 0 to 3, with higher scores indicating better reperfusion. mTICI 0: No antegrade reperfusion; mTICI 1: Antegrade reperfusion past initial occlusion, limited distal filling; mTICI 2a: Antegrade reperfusion of less than half (<50%) of the previously occluded target artery's ischemic territory; mTICI 2b: Antegrade reperfusion of more than half (≥50%) of the previously occluded target artery's ischemic territory; mTICI 2c: Near-complete (90-99%) reperfusion, or filling of all distal branches with slower flow; mTICI 3: Complete antegrade reperfusion of all branches |
Intraprocedural
|
|
Proportion of cases with clot ingestion, as evidenced by clot captured within the Zoom POD
時間枠:Intraprocedural
|
Proportion of cases with clot ingestion, as evidenced by clot captured within at least one of the Zoom PODs |
Intraprocedural
|
|
Proportion of cases with clot captured within the Zoom POD connected to the outer aspiration catheter
時間枠:Intraprocedural
|
Proportion of cases with clot ingestion, as evidenced by clot captured within the outer Zoom PODs |
Intraprocedural
|
|
Rate of rescue therapy
時間枠:Intraprocedural
|
Proportion of cases with rescue therapy, defined as unplanned use of another manufacturer's thrombectomy device, angioplasty, or stenting within the target vessel territory to achieve mTICI≥2c. |
Intraprocedural
|
|
Rate of functional independence (mRS 0-2) at 90 days
時間枠:90 days post-procedure
|
Proportion of patients achieving mRS (modified Rankin Scale) ≤2 at 90 days mRS range: 0 to 6; The mRS scale ranges from 0 (no symptoms) to 5 (severe disability), with an additional category of 6 for death; higher score means worse outcome |
90 days post-procedure
|
|
Proportion of patients achieving First Pass Effect (FPE) mTICI ≥2c as adjudicated by independent core-lab
時間枠:Intraprocedural
|
Proportion of cases achieving First Pass Effect (FPE), defined as mTICI ≥2c after the first pass with the study device and technique as adjudicated by independent core-lab mTICI scale ranges from 0 to 3, with higher scores indicating better reperfusion. mTICI 0: No antegrade reperfusion; mTICI 1: Antegrade reperfusion past initial occlusion, limited distal filling; mTICI 2a: Antegrade reperfusion of less than half (<50%) of the previously occluded target artery's ischemic territory; mTICI 2b: Antegrade reperfusion of more than half (≥50%) of the previously occluded target artery's ischemic territory; mTICI 2c: Near-complete (90-99%) reperfusion, or filling of all distal branches with slower flow; mTICI 3: Complete antegrade reperfusion of all branches |
Intraprocedural
|
|
Rate of symptomatic intracranial hemorrhage (sICH), as confirmed by imaging and independently adjudicated by medical monitor, at the 24-hour post-procedure
時間枠:24-hour post-procedure
|
Independently adjudicated rate of symptomatic intracranial hemorrhage (sICH) defined as any apparently extravascular blood in the brain or within the cranium confirmed by imaging that is associated with clinical deterioration as defined by an increase of four or more points in the NIHSS at 24 hours compared to the baseline assessment, or that led to death, and was judged to be the predominant cause of a neurologic deterioration or death, per ECASS III criteria |
24-hour post-procedure
|
|
90-day all-cause mortality
時間枠:90 days post-procedure
|
Rate of all-cause mortality through 90 days post-procedure |
90 days post-procedure
|
|
Rate of device-related Serious Adverse Events, independently adjudicated medical monitor
時間枠:Intraprocedural
|
Independently adjudicated rate of Serious Adverse Events related to study device |
Intraprocedural
|
協力者と研究者
捜査官
捜査官
- 主任研究者:David Fiorella, MD、Stony Brook University
- 主任研究者:Shahram Majidi, MD、Icahn School of Medicine at Mount Sinai
- 主任研究者:Justin Masciteli, MD、The University of Texas Health Science Center at San Antonio
- 主任研究者:Maxim Mokin, MD、University of South Florida
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- ICI-2025-003
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。